Compounds, targets and pathways for macrophage modulation
AssigneeMassachusetts Institute of Technology
InventorsJianzhu Chen, Guangan Hu
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of modulating macrophage activation to treat various diseases, such as cancer, fibrosis, infectious diseases, inflammatory diseases, metabolic diseases, or autoimmune diseases. Also disclosed are methods of identifying compounds useful for modulating macrophage activation as means to treat cancer, fibrosis, infectious diseases, inflammatory diseases, metabolic diseases, or autoimmune diseases.
Claims26
A method of identifying a modulator of macrophage activation, comprising:
- contacting a primary macrophage cell with a candidate agent;
- monitoring or photographing the morphology of the cell contacted with the candidate agent;
- and
- optionally comparing the cell's morphology in the presence of the candidate agent with the cell's morphology in the absence of the candidate agent;
- wherein a change in morphology in the presence of the candidate agent is indicative of modulation of macrophage activation.
-6. (canceled)
-23. (canceled)
-33. (canceled)
-38. (canceled)
A method of treating cancer, fibrosis, or an infectious disease, comprising administering to a subject in need thereof an effective amount of a modulator of macrophage activation;
- wherein the modulator changes the morphology of a macrophage cell from elongated shape to round shape or the modulator activates a serotonin transporter or receptor, a histamine transporter or receptor, a dopamine transporter or receptor, an adrenoceptor, VEGF, EGF and/or leptin.
-62. (canceled)
A method of treating an inflammatory disease, a metabolic disease, an autoimmune disease, or a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a modulator of macrophage activation;
- wherein the modulator changes the morphology of a macrophage cell from round shape to elongated shape, the modulator inhibits a serotonin transporter or receptor, a histamine transporter or receptor, a dopamine transporter or receptor, an adrenoceptor, VEGF, EGF and/or leptin, or the modulator is diphenyleneiodonium (DPI).
-96. (canceled)
Dependencies are inferred from the claim text.